Valuation: Cadrenal Therapeutics, Inc.

Market Cap 5.67M 4.86M 4.55M 4.16M 7.81M 543M 7.91M 53.72M 20.95M 273M 21.3M 20.84M 902M P/E 2026 *
-0.41x
P/E 2027 * -0.49x
Enterprise Value 5.67M 4.86M 4.55M 4.16M 7.81M 543M 7.91M 53.72M 20.95M 273M 21.3M 20.84M 902M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
88.07%
Yield 2026 *
-
Yield 2027 * -
1 day-1.26%
1 week-15.78%
Current month-21.64%
1 month-27.42%
3 months-69.54%
6 months-76.53%
Current year-76.77%
1 week 1.54
Extreme 1.541
1.88
1 month 1.54
Extreme 1.541
2.24
Current year 1.54
Extreme 1.541
8.96
1 year 1.54
Extreme 1.541
14.64
3 years 1.54
Extreme 1.541
32.55
5 years 1.54
Extreme 1.541
101.25
10 years 1.54
Extreme 1.541
101.25
Manager TitleAgeSince
Chief Executive Officer 61 25/01/2022
Director of Finance/CFO 61 25/06/2026
Chief Operating Officer 58 06/02/2024
Director TitleAgeSince
Director/Board Member 76 19/01/2023
Director/Board Member 78 19/01/2023
Chairman 61 25/01/2022
Date Insider Type Main position Quantity % Market Cap.
29/12/25 Sell

Founder

9,933 0.4785%
02/12/25 Free

Director

5,000 0.2409%
24/11/25 Other

Director

1,667 0.0814%
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%-15.78%-87.35%-86.59% 5.67M
-3.00%+0.33%+77.39%+109.41% 73.96B
+1.90%+23.53%+56.60%+97.76% 64.66B
+0.90%+2.03%-4.79%+473.89% 27.32B
+4.01%+22.83%+3.22%-2.71% 27.86B
+2.74%+11.55%+66.56%+27.34% 25.97B
+0.47%+6.12%+36.66%-13.79% 19.98B
+1.82%-3.11%+245.72%+423.83% 17.84B
+0.94%+2.38%+24.83%+552.12% 16.24B
+1.03%+5.58%+39.76%+153.16% 13.3B
Average +0.98%+4.09%+45.86%+173.44% 28.71B
Weighted average by Cap. +0.64%+6.66%+59.62%+161.19%

Financials

2026 *2027 *
Net sales - -
Net income -12.5M -10.71M -10.02M -9.17M -17.21M -1.2B -17.44M -118M -46.16M -601M -46.94M -45.92M -1.99B -19.7M -16.88M -15.79M -14.45M -27.13M -1.88B -27.48M -187M -72.75M -947M -73.97M -72.36M -3.13B
Net Debt - -
Logo Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
Employees
-
Date Price Change Volume
21/08/26 $1.575 -0.94% 28,921
20/08/26 $1.590 -3.05% 59,973
19/08/26 $1.640 -4.09% 81,000
18/08/26 $1.710 -2.84% 59,491
17/08/26 $1.760 -5.88% 37,199
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.590USD
Average target price
14.00USD
Spread / Average Target
+780.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CVKD Stock